efegatran has been researched along with Myocardial Infarction in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kleiman, NS | 1 |
| Cambier, PA; Every, NR; Fung, AY; Hallstrom, AP; Hansen, D; Lee, JJ; Lorch, G; Martin, JS; Scherer, J; Stock-Novack, D; Titus, BG; Weaver, WD | 1 |
2 review(s) available for efegatran and Myocardial Infarction
| Article | Year |
|---|---|
Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Platelets; Clinical Trials as Topic; Epoprostenol; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin; Thrombolytic Therapy | 1996 |
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Topics: Angina, Unstable; Antithrombins; Arginine; Glycine; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Survival Rate; Thrombin | 2002 |
2 trial(s) available for efegatran and Myocardial Infarction
| Article | Year |
|---|---|
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Topics: Antithrombins; Cardiac Catheterization; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Streptokinase; Tissue Plasminogen Activator; Vascular Patency | 1999 |
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Patient Selection; Recurrence; Regression Analysis; Treatment Failure | 2002 |